// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

A Multi-Center Analysis of Risk Factors for Pneumocystis Pneumonia (PCP) in Solid Organ Transplant Recipients

S. Hosseini-Moghaddam - American Transplant Congress (ATC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

N/A

A Proteomic Analysis of Kidneys Subjected to Normothermic Ex Vivo Kidney Perfusion (NEVKP) Demonstrates That Metabolism is an Important Determinant of Kidney Function Following Warm Ischemia

A. Konvalinka - American Transplant Congress (ATC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

N/A

N/A

A Research-Informed Framework for a Medication Adherence Intervention to Support Transition of Adolescent Kidney Recipients to Independent Medication-Taking

T. Irizarry - American Transplant Congress (ATC) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

ABO Tolerance after Treatment of Infant or Adult Mice with MHC-Matched A-Expressing Blood Cells

B. Motyka - American Transplant Congress (ATC) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

An Economic Analysis of the UK Pancreas Allocation Scheme

K. Burke - American Transplant Congress (ATC) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

An In Vitro Model of Human Antibody-Mediated Rejection Depicts Key Role for NK Cells

L. Hidalgo - American Transplant Congress (ATC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

An Open-Label Proof-of-Principle Phase 2a Study to Evaluate Autologous Hematopoietic Stem Cell Transplantation for Allogeneic Organ Transplant Tolerance (ASCOTT)

A. Chruscinski - American Transplant Congress (ATC) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Cyclophosphamide

Anti-Angiotensin II Type 1-Receptor Antibodies (AT1R-Ab) Induce a Specific Phenotype of Rejection Distinct from HLA Antibody-Mediated Rejection

C. Lefaucheur - American Transplant Congress (ATC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Angiotensin II

Antibody-Verified Eplet Mismatches as Determinants of Premature Kidney Transplant Loss

R. Sapir-Pichhadze - American Transplant Congress (ATC) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Antihypertensive Medication Use after Kidney Transplant: Practice Variation and Clinical Outcomes

H. Yamout - American Transplant Congress (ATC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

Angiotensin II

Apoptotic Exosome-Like Vesicles Induce Endothelial Cell Plasticity

F. Migneault - American Transplant Congress (ATC) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Are Deceased Donor Characteristics Associated with Liver Graft Failure among Low MELD Patients Receiving a Liver Transplant Changing

K. Atiemo - American Transplant Congress (ATC) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Assessment of Bile Production and Quality during Normothermic Ex Vivo Liver Perfusion to Predict Biliary Injury

D. Kollmann - American Transplant Congress (ATC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

AT1R Antibody Analysis: High Proportion of Non-Specific Reactivity?

A. Halpin - American Transplant Congress (ATC) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Lanthanum carbonate

Attitudes of African Canadian Patients with End Stage Kidney Disease toward Living Donor Kidney Transplantation

V. Gupta - American Transplant Congress (ATC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Nephrology

N/A

N/A

Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection – A Double-Blind Randomized Placebo-Controlled Trial (BORTEJECT Study)

F. Eskandary - American Transplant Congress (ATC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Bortezomib

Calcineurin Inhibitors, Macrolides, and the Risk of Adverse Drug Events in Kidney Transplant Recipients

RachelH.Jeong - American Society of Nephrology (ASN) , 2018

Therapeutic Area

Disease

Drug/Treatment

Nephrology

N/A

Biaxin

Cannabis Dependence or Abuse before and after Kidney Transplantation: Implications for Post-Transplant Outcomes

K. Lentine - American Transplant Congress (ATC) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Characterization of Mycobacterium Tuberculosis Memory T Cell Subsets in Solid Organ Transplant Recipients with Previously Treated Active Tuberculosis

S. Nellimarla - American Transplant Congress (ATC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

N/A

N/A

Chronic Antibody Mediated Rejection in Renal Allografts Shows RNA Transcript Patterns That Evolve with Stage

A. Rosales - American Transplant Congress (ATC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved